Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Recently, the US Preventive Services Task Force (USPSTF) published a review of the evidence for screening for prostate cancer1 and made a clear recommendation against screening. By giving a grade of “D” in the recommendation statement that was based on this review, the USPSTF concluded that “there is moderate or high certainty that this service has no net benefit or that the harms outweigh the benefits.” 2(p3)

[1]  A. Zietman,et al.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. , 2000, JAMA.

[2]  Andrew J Vickers,et al.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. , 2011, Journal of the National Cancer Institute.

[3]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[4]  E. Metter,et al.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[6]  H. D. de Koning,et al.  Short-term effects of population-based screening for prostate cancer on health-related quality of life. , 1998, Journal of the National Cancer Institute.

[7]  P. Scardino,et al.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50 , 2011, Cancer.

[8]  C. Sima,et al.  Cancer screening among patients with advanced cancer. , 2010, JAMA.

[9]  Adam S. Kibel,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .

[10]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[11]  S. Yao,et al.  Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. , 1999, Journal of the National Cancer Institute.

[12]  J. Eastham.  Do high-volume hospitals and surgeons provide better care in urologic oncology? , 2009, Urologic oncology.

[13]  S. Carlsson.  Prostate cancer screening with PSA - A study of potential negative consequences , 2010 .

[14]  M. Roobol,et al.  ERSPC and PLCO prostate cancer screening studies: what are the differences? , 2010, European urology.

[15]  Ruth Etzioni,et al.  Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. , 2011, Journal of clinical epidemiology.

[16]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[17]  M. Kattan,et al.  The surgical learning curve for prostate cancer control after radical prostatectomy , 2008 .

[18]  J. Hugosson,et al.  Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. , 2007, European journal of cancer.

[19]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Prorok,et al.  Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.

[21]  Antoinette M Stroup,et al.  Prostate cancer early detection , 2010 .

[22]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[23]  Colin B Begg,et al.  Variations in morbidity after radical prostatectomy. , 2002, The New England journal of medicine.

[24]  A. Vickers,et al.  Low annual caseloads of United States surgeons conducting radical prostatectomy. , 2009, The Journal of urology.

[25]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[26]  T. H. van der Kwast,et al.  Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. , 2001, Urology.

[27]  Antoinette M Stroup,et al.  NCCN clinical practice guidelines in oncology: prostate cancer early detection. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  P. Albertsen,et al.  Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study. , 1999, Urology.

[29]  P. Scardino,et al.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.

[30]  F. Hamdy,et al.  Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? , 2009, European journal of cancer.

[31]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[32]  F. Hamdy,et al.  Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK , 2006, BJU international.

[33]  T. Wilt,et al.  Screening for prostate cancer: an updated Cochrane systematic review , 2011, BJU international.

[34]  M. Barry,et al.  One man at a time--resolving the PSA controversy. , 2011, The New England journal of medicine.

[35]  M. Roobol,et al.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.

[36]  P. Stattin,et al.  Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden , 2009, Scandinavian journal of urology and nephrology.

[37]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[38]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[39]  R. Beyth,et al.  Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[40]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[41]  S. Eggener,et al.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.